{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:25:54Z","timestamp":1783527954051,"version":"3.55.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T00:00:00Z","timestamp":1702512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Hum. Neurosci."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Serum neurofilament light chain (S NfL) is a non-specific marker of neuronal damage, including Alzheimer\u2019s disease (AD). We aimed to verify the reference interval (RI) of serum NfL using a highly sensitive ELISA, and to estimate the optimal cut-off value for neuronal damage. Our second objective was to compare NfL in cerebrospinal fluid (CSF) and serum (S) with the routine neurodegeneration biomarkers used in AD, and to assess their concentrations relative to the degree of cognitive deficit.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Samples from 124 healthy volunteers were used to estimate the S NfL RI. For the comparison study, we used CSF and S samples from 112 patients with cognitive disorders. Cognitive functions were assessed using the mini-mental state examination. ELISA assays were used to determine the CSF and S NfL levels, CSF \u03b2-amyloid peptide<jats:sub>42<\/jats:sub> (A\u03b2<jats:sub>42<\/jats:sub>), CSF \u03b2-amyloid peptide<jats:sub>40<\/jats:sub> (A\u03b2<jats:sub>40<\/jats:sub>), CSF total tau protein (tTau), CSF phosphorylated tau protein (pTau), and CSF alpha-synuclein (\u03b1S).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The estimated RI of S NfL were 2.25\u20139.19 ng.L<jats:sup>\u20131<\/jats:sup>. The cut-off value of S NfL for assessing the degree of neuronal impairment was 10.5 ng.L<jats:sup>\u20131<\/jats:sup>. We found a moderate statistically significant correlation between S NfL and CSF A\u03b2<jats:sub>42<\/jats:sub> in the group with movement disorders, without dementia (<jats:italic>r<\/jats:italic><jats:sub><jats:italic>s<\/jats:italic><\/jats:sub> = 0.631; <jats:italic>p<\/jats:italic> = 0.016); between S NfL and CSF A\u03b2<jats:sub>40<\/jats:sub> in the group with movement disorder plus dementia (<jats:italic>r<\/jats:italic><jats:sub><jats:italic>s<\/jats:italic><\/jats:sub> = \u22120.750; <jats:italic>p<\/jats:italic> = 0.052); between S NfL and CSF tTau in the control group (<jats:italic>r<\/jats:italic><jats:sub><jats:italic>s<\/jats:italic><\/jats:sub> = 0.689; <jats:italic>p<\/jats:italic> = 0.009); and between S NfL and CSF pTau in the control group (<jats:italic>r<\/jats:italic><jats:sub><jats:italic>s<\/jats:italic><\/jats:sub> = 0.749; <jats:italic>p<\/jats:italic> = 0.003). The non-parametric Kruskal\u2013Wallis test revealed statistically significant differences between S NfL, CSF NfL, CSF A\u03b2<jats:sub>42<\/jats:sub>, CSF tTau, and CSF pTau and diagnosis within groups. The highest kappa coefficients were found between the concentrations of S NfL and CSF NfL (\u03ba = 0.480) and between CSF NfL and CSF tTau (\u03ba = 0.351).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our results suggested that NfL and tTau in CSF of patients with cognitive decline could be replaced by the less-invasive determination of S NfL using a highly sensitive ELISA method. S NfL reflected the severity of cognitive deficits assessed by mini-mental state examination (MMSE). However, S NfL is not specific to AD and does not appear to be a suitable biomarker for early diagnosis of AD.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fnhum.2023.1284416","type":"journal-article","created":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T17:22:45Z","timestamp":1702574565000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Serum neurofilament light chain levels in patients with cognitive deficits and movement disorders: comparison of cerebrospinal and serum neurofilament light chain levels with other biomarkers"],"prefix":"10.3389","volume":"17","author":[{"given":"Richard","family":"Novobilsk\u00fd","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Bartova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Lich\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Bar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Stejskal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavl\u00edna","family":"Kusnierova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,12,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.neurobiolaging.2020.07.018","article-title":"Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimer\u2019s disease.","volume":"95","author":"Andersson","year":"2020","journal-title":"Neurobiol. Aging"},{"key":"B2","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1212\/WNL.0000000000003085","article-title":"Neurofilament light chain level is a weak risk factor for the development of MS.","volume":"87","author":"Arrambide","year":"2016","journal-title":"Neurology."},{"key":"B3","doi-asserted-by":"crossref","first-page":"533","DOI":"10.14735\/amcsnn2019533","article-title":"Determination of tau proteins and \u03b2-amyloid 42 in cerebrospinal fluid by ELISA methods and indicative normative values.","author":"Barto\u0161","year":"2019","journal-title":"\u00c8esk\u00e1 Slov. Neurol. Neurochir."},{"key":"B4","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1136\/jnnp.2008.166447","article-title":"The oldest old Creutzfeldt-Jakob disease case.","volume":"80","author":"Buganza","year":"2009","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2021.717930","article-title":"Detection of cerebrospinal fluid neurofilament light Chain as a marker for alpha-synucleinopathies.","volume":"13","author":"Canaslan","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"B6","doi-asserted-by":"publisher","first-page":"850","DOI":"10.4103\/1673-5374.268971","article-title":"Neurodegenerative diseases as proteinopathies-driven immune disorders.","volume":"15","author":"Ciccocioppo","year":"2020","journal-title":"Neural. Regen. Res."},{"key":"B7","year":"2008","journal-title":"Defining, establishing, and verifying reference intervals in the clinical laboratory; approved guideline"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23137221","article-title":"A Novel neurofilament light chain ELISA validated in patients with Alzheimer\u2019s disease, frontotemporal dementia, and subjective cognitive decline, and the evaluation of candidate proteins for immunoassay calibration.","volume":"23","author":"Das","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.1034684","article-title":"Neurofilaments contribution in clinic: State of the art.","volume":"14","author":"Delaby","year":"2022","journal-title":"Front. Aging Neurosci."},{"key":"B10","article-title":"Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer\u2019s disease.","volume":"12","author":"Dhiman","year":"2020","journal-title":"Alzheimer\u2019s Dement. (Amsterdam, Netherlands)"},{"key":"B11","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028035","article-title":"Pathology of neurodegenerative diseases.","volume":"9","author":"Dugger","year":"2017","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"B12","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1016\/S0140-6736(05)67889-0","article-title":"Global prevalence of dementia: A Delphi consensus study.","volume":"366","author":"Ferri","year":"2005","journal-title":"Lancet (London, England)"},{"key":"B13","doi-asserted-by":"publisher","first-page":"4270","DOI":"10.1007\/s00415-022-11055-5","article-title":"Plasma neurofilament light chain as a biomarker of Alzheimer\u2019s disease in Subjective Cognitive Decline and Mild Cognitive Impairment.","volume":"269","author":"Giacomucci","year":"2022","journal-title":"J. Neurol."},{"key":"B14","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/acn3.51524","article-title":"Development of an age-adjusted model for blood neurofilament light chain.","volume":"9","author":"Harp","year":"2022","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"B15","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23137307","article-title":"Tau as a biomarker of neurodegeneration.","volume":"23","author":"Holper","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1080\/00365513.2020.1730434","article-title":"Reference interval and preanalytical properties of serum neurofilament light chain in Scandinavian adults.","volume":"80","author":"Hviid","year":"2020","journal-title":"Scand. J. Clin. Lab. Invest."},{"key":"B17","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nrn3549","article-title":"Parkinson\u2019s disease dementia: Convergence of \u03b1-synuclein, tau and amyloid-\u03b2 pathologies.","volume":"14","author":"Irwin","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: Toward a biological definition of Alzheimer\u2019s disease.","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement."},{"key":"B19","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s00401-016-1552-2","article-title":"CSF biomarkers associated with disease heterogeneity in early Parkinson\u2019s disease: the Parkinson\u2019s progression markers initiative study.","volume":"131","author":"Kang","year":"2016","journal-title":"Acta Neuropathol."},{"key":"B20","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","article-title":"Neurofilaments as biomarkers in neurological disorders.","volume":"14","author":"Khalil","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"25729","DOI":"10.18632\/aging.203790","article-title":"Factors influencing serum neurofilament light chain levels in normal aging.","volume":"13","author":"Koini","year":"2021","journal-title":"Aging (Albany NY)."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-020-00696-1","article-title":"Cerebrospinal fluid A beta 1-40 peptides increase in Alzheimer\u2019s disease and are highly correlated with phospho-tau in control individuals.","volume":"12","author":"Lehmann","year":"2020","journal-title":"Alzheimers Res. Ther."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2020.00579","article-title":"Neurofilament-light chain as biomarker of neurodegenerative and rare diseases with high translational value.","volume":"14","author":"Loeffler","year":"2020","journal-title":"Front. Neurosci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.3233\/JPD-212535","article-title":"Serum neurofilament dynamics predicts cognitive progression in de novo Parkinson\u2019s disease.","volume":"11","author":"Ma","year":"2021","journal-title":"J. Parkinsons Dis."},{"key":"B25","doi-asserted-by":"crossref","first-page":"276","DOI":"10.11613\/BM.2012.031","article-title":"Interrater reliability: The kappa statistic.","volume":"22","author":"McHugh","year":"2012","journal-title":"Biochem. Med."},{"key":"B26","first-page":"S65","article-title":"Frontotemporal dementia: An updated overview.","author":"Mohandas","year":"2009","journal-title":"Indian J. Psychiatry."},{"key":"B27","doi-asserted-by":"publisher","first-page":"S76","DOI":"10.1016\/S1353-8020(13)70020-8","article-title":"Quantification of \u03b1-synuclein in cerebrospinal fluid: How ideal is this biomarker for Parkinson\u2019s disease?","author":"Mollenhauer","year":"2014","journal-title":"Parkinsonism Relat. Disord."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1002\/mds.28206","article-title":"Validation of serum neurofilament light Chain as a biomarker of Parkinson\u2019s disease progression.","volume":"35","author":"Mollenhauer","year":"2020","journal-title":"Mov. Disord."},{"key":"B29","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1474-4422(18)30403-4","article-title":"Global, regional, and national burden of Alzheimer\u2019s disease and other dementias, 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016.","volume":"18","author":"Nichols","year":"2019","journal-title":"Lancet Neurol."},{"key":"B30","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/mds.27897","article-title":"CSF or serum neurofilament light added to \u03b1-Synuclein panel discriminates Parkinson\u2019s from controls.","volume":"35","author":"Oosterveld","year":"2020","journal-title":"Mov. Disord."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1128\/CVI.00112-10","article-title":"Resampling approach for determination of the method for reference interval calculation in clinical laboratory practice.","volume":"17","author":"Pavlov","year":"2010","journal-title":"Clin. Vaccine Immunol."},{"key":"B32","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson\u2019s disease.","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov. Disord."},{"key":"B33","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41591-018-0304-3","article-title":"Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer\u2019s disease.","volume":"25","author":"Preische","year":"2019","journal-title":"Nat. Med."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104177","article-title":"Serum neurofilament levels in patients with multiple sclerosis: A comparison of SIMOA and high sensitivity ELISA assays and contributing factors to ELISA levels.","volume":"67","author":"Revendova","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"B35","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000089361","article-title":"Vascular dementia prevention: A risk factor analysis.","author":"Rom\u00e1n","year":"2005","journal-title":"Cerebrovasc. Dis."},{"key":"B36","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1212\/WNL.0b013e3181f39a78","article-title":"CSF amyloid \u03b2 1-42 predicts cognitive decline in Parkinson disease.","volume":"75","author":"Siderowf","year":"2010","journal-title":"Neurology"},{"key":"B37","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-014-0077-y","article-title":"Evaluating the relationship between amyloid-\u03b2 and \u03b1-synuclein phosphorylated at Ser129 in dementia with Lewy bodies and Parkinson\u2019s disease.","volume":"6","author":"Swirski","year":"2014","journal-title":"Alzheimers Res. Ther."},{"key":"B38","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.parkreldis.2022.07.007","article-title":"Clinical correlations of cerebrospinal fluid biomarkers including neuron-glia 2 and neurofilament light chain in patients with multiple system atrophy.","volume":"102","author":"Tokutake","year":"2022","journal-title":"Parkinsonism Relat. Disord."},{"key":"B39","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s00401-013-1121-x","article-title":"Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease.","volume":"126","author":"Zhang","year":"2013","journal-title":"Acta Neuropathol."}],"container-title":["Frontiers in Human Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnhum.2023.1284416\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T17:22:58Z","timestamp":1702574578000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnhum.2023.1284416\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,14]]},"references-count":39,"alternative-id":["10.3389\/fnhum.2023.1284416"],"URL":"https:\/\/doi.org\/10.3389\/fnhum.2023.1284416","relation":{},"ISSN":["1662-5161"],"issn-type":[{"value":"1662-5161","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,14]]},"article-number":"1284416"}}